Page last updated: 2024-12-11

4,7,10,13,16,19-docosahexaenoic acid ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,7,10,13,16,19-docosahexaenoic acid ethyl ester: RN given refers to compound with specified unsaturation and no isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6381521
CHEBI ID95352
MeSH IDM0185028

Synonyms (22)

Synonym
LS-15069
docosahexaenoic acid ethyl ester
dh-ethyl ester
cis-4,7,10,13,16,19-docosahexaenoic acid ethyl ester, >=97%
ethyl (4e,7e,10e,13e,16e,19e)-docosa-4,7,10,13,16,19-hexaenoate
cis-4,7,10,13,16,19-docosahexaenoic acid ethyl ester
84494-72-4
ethyl docosa-4,7,10,13,16,19-hexaenoate
ethyl docosahexaenoate
4,7,10,13,16,19-docosahexaenoic acid, ethyl ester
4,7,10,13,16,19-docosahexaenoic acid ethyl ester
incromega dha 700esr
AKOS015902558
J-000561
mfcd00673477
CHEBI:95352
cis-4,7,10,13,16,19-docosahexaenoic*acid ethyl es
(4e,7e,10e,13e,16e,19e)-ethyl docosa-4,7,10,13,16,19-hexaenoate
docosa-4,7,10,13,16,19-hexaenoic acid ethyl ester
CS-W011836
CS-15570
HY-W011120

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully applied to a pharmacokinetic study of EPAEE and DHAEE in healthy Chinese volunteers after the oral administration of 4 g omega-3-acid ethyl esters 90 soft capsule."( LC-APCI-MS/MS assay for quantitation of ethyl esters of eicosapentaenoic acid and docosahexaenoic acid in human plasma and its application in a pharmacokinetic study.
Ding, L; Ji, S; Li, L; Xia, Y; Zhao, S, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The relative oral bioavailability (F(r)) of DHA-ME in comparison to Neoral was determined to be 114%, while the F(r) of VE-ME was only 60%."( Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.
Hirunpanich, V; Sato, H, 2009
)
0.35
"The present results, in fasted low-fat diet fed rats, are consistent with higher oral bioavailability of OM3CA versus OM3EE forms of DHA."( Uptake and tissue accretion of orally administered free carboxylic acid as compared to ethyl ester form of docosahexaenoic acid (DHA) in the rat.
Ericsson, C; Hagstedt, T; Kjellstedt, A; Lindblom, A; Oakes, ND; Oscarsson, J, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" In addition, we aimed to obtain preliminary information regarding EPA half-life, which is needed to establish an optimal dosing schedule."( Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions.
Dagnelie, PC; Rietveld, T; van den Berg, JW; Wilson, JH; Zuijdgeest-van Leeuwen, SD, 1999
)
0.3
"The dose-response effect of dietary docosahexaenoic acid (DHA, 22:6 n-3) ethyl ester (EE) on maze-learning ability in mice was studied."( Dose-response effect of docosahexaenoic acid ethyl ester on maze behavior and brain fatty acid composition in adult mice.
Lim, SY; Suzuki, H, 2002
)
0.31
"The aim of this study was to compare the plasma exposure and tissue accretion of docosahexaenoic acid (DHA) in response to oral dosing of free carboxylic acid (OM3CA) and ethyl ester (OM3EE) forms."( Uptake and tissue accretion of orally administered free carboxylic acid as compared to ethyl ester form of docosahexaenoic acid (DHA) in the rat.
Ericsson, C; Hagstedt, T; Kjellstedt, A; Lindblom, A; Oakes, ND; Oscarsson, J, 2018
)
0.48
" Once DHA has entered the circulation, the tissue distribution is independent of the dosed form and uptake in the skeletal muscle, fat and brain is driven by the polar pools of DHA in plasma, while DHA accretion in liver is supplied by both polar and neutral plasma lipids."( Uptake and tissue accretion of orally administered free carboxylic acid as compared to ethyl ester form of docosahexaenoic acid (DHA) in the rat.
Ericsson, C; Hagstedt, T; Kjellstedt, A; Lindblom, A; Oakes, ND; Oscarsson, J, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (37.74)18.2507
2000's17 (32.08)29.6817
2010's14 (26.42)24.3611
2020's2 (3.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.29 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (7.02%)5.53%
Reviews1 (1.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (91.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]